Myriad Genetics Inc. filings document the regulatory record of a molecular diagnostics and precision medicine company. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary revenue and test-volume information, guidance, and product-related operating updates tied to Cancer Care Continuum, Prenatal Health, Mental Health, Precise MRD, and MyChoice CDx.
The company's proxy materials cover board matters, executive compensation, equity awards, and annual meeting governance. Other current reports document officer transitions, compensatory arrangements, and amendments to previously furnished earnings materials, providing formal disclosure of governance changes and financial-reporting corrections.
Myriad Genetics Chief Scientific Officer Dale Muzzey reported a routine tax-related share withholding. On March 22, 2026, 2,019 shares of Myriad Genetics common stock were withheld by the company at $4.58 per share to cover tax obligations from vesting restricted stock units.
These shares were not sold in the open market but delivered back to the issuer to satisfy taxes. After this tax-withholding disposition, Muzzey directly holds 327,256 shares of Myriad Genetics common stock, indicating the transaction affects only a small portion of his overall equity position.
Myriad Genetics Chief Operating Officer Mark Verratti reported a routine tax-related share withholding. On March 22, 2026, 2,055 shares of Common Stock were disposed of at $4.58 per share to satisfy tax obligations tied to vesting restricted stock units. The number of shares withheld was based on the March 20, 2026 closing price. After this withholding, Verratti directly owns 630,715 shares of Myriad Genetics Common Stock.
MYRIAD GENETICS INC Chief Financial Officer Benjamin Richard Wheeler had 549 shares of Common Stock withheld by the company to cover tax obligations tied to restricted stock unit vesting. The withheld shares were valued at $4.58 per share, based on the closing price on March 20, 2026.
These shares were not sold in the open market but retained by the issuer to satisfy tax withholding requirements. After this tax-withholding disposition, Wheeler directly holds 298,509 shares of Myriad Genetics common stock.
MYRIAD GENETICS INC Chief Technology Officer Kevin Richard Haas reported share dispositions that were entirely for tax withholding. Over March 13–15, 2026, a total of 22,310 shares of Common Stock were withheld by the company to satisfy tax obligations from vesting restricted and performance-based stock units.
These F-code transactions are not open-market sales and do not reflect discretionary selling activity. After these tax-withholding events, Haas continues to hold 180,022 shares of Common Stock directly.
MYRIAD GENETICS INC Chief People Officer Shereen Solaiman received a large equity award and had shares withheld for taxes. On March 12, 2026, she was granted 173196 time-based restricted stock units under the 2017 equity incentive plan, vesting in three equal annual installments starting on the first anniversary of the grant.
On March 13 and 14, 2026, the company withheld 8899 and 5784 shares of common stock, respectively, to cover tax obligations tied to vesting of previously granted restricted stock units, based on a share price of $4.6600. After these tax-withholding dispositions, she directly holds 267801 shares of common stock.
Myriad Genetics Chief Scientific Officer Dale Muzzey reported equity compensation activity and related tax withholding transactions in company stock. On March 12, 2026, he received 173,196 time-based restricted stock units under the 2017 equity incentive plan, each representing one share of common stock vesting in three equal annual installments beginning on the first anniversary of the grant.
On March 13–15, 2026, a total of 37,799 shares of common stock were withheld by the company at $4.66 per share to satisfy tax obligations on the vesting of previously granted time-based and performance-based restricted stock units. These F-code transactions are share-withholding for taxes rather than open-market sales. After these transactions, Muzzey directly holds 329,275 shares of common stock.
MYRIAD GENETICS INC Chief Legal Officer Jennifer Lynne Fox reported equity compensation and related tax withholding transactions in company common stock. On March 12, 2026, she acquired 195,876 time-based restricted stock units granted under the 2017 Employee, Director and Consultant Equity Incentive Plan, with each unit representing one share of common stock that vests in three equal annual installments beginning on the first anniversary of the grant date. On March 13, 2026, 5,995 shares were withheld by the company at a price of $4.66 per share to satisfy tax obligations related to previously vesting restricted stock units. Following these transactions, she directly holds 310,362 shares of common stock.
Donnelly Brian J reported acquisition or exercise transactions in this Form 4 filing.
MYRIAD GENETICS INC Chief Commercial Officer Brian J. Donnelly reported an equity compensation grant of 226,804 shares of common stock in the form of time-based restricted stock units at a price of $0.00 per share.
Each restricted stock unit represents a contingent right to receive one share of common stock and will vest in three equal annual installments beginning on the first anniversary of the grant date. Following this award, Donnelly holds 624,338 shares of common stock directly.
Myriad Genetics’ Chief Operating Officer Mark Verratti reported routine equity compensation activity. On March 12, 2026, he acquired 247,423 time-based restricted stock units, each representing one future share that vests in three equal annual installments starting one year after the grant.
On March 13–15, 2026, a total of 29,289 shares of common stock were withheld at $4.66 per share to cover tax obligations tied to the vesting of previously granted time-based and performance-based restricted stock units. After these transactions, Verratti directly held 632,770 shares of Myriad Genetics common stock.
Myriad Genetics Chief Financial Officer Benjamin Richard Wheeler reported equity compensation and related tax withholding transactions in company common stock. On March 12, 2026, he received 206,186 time-based restricted stock units, each representing one future share, vesting in three equal annual installments beginning on the first anniversary of the grant date.
Between March 13 and March 15, 2026, a total of 4,752 shares of common stock were withheld by the company to cover tax obligations tied to vesting of previously granted time-based and performance-based restricted stock units. These are tax-withholding dispositions rather than open-market sales. After these transactions, Wheeler directly holds 299,058 shares of Myriad Genetics common stock.